February 27th 2024
Long-term treatment showed increased efficacy in patients who responded partially in week 52, indicating the importance of extended therapy for maximizing benefits in certain individuals.
February 15th 2024
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
March 9, 2024
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia